<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00945347</url>
  </required_header>
  <id_info>
    <org_study_id>MIG-99</org_study_id>
    <nct_id>NCT00945347</nct_id>
  </id_info>
  <brief_title>Does a Nasal Instillation of Miglustat Normalize the Nasal Potential Difference in Cystic Fibrosis Patients ?</brief_title>
  <official_title>Does a Nasal Instillation of Miglustat Normalize the Nasal Potential Difference in Cystic Fibrosis Patients Homozygous for the F508del Mutation? A Randomized, Double Blind Placebo-controlled Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cliniques universitaires Saint-Luc- Université Catholique de Louvain</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cliniques universitaires Saint-Luc- Université Catholique de Louvain</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate within a short delay the effect of nasal
      instillation of Miglustat on nasal potential difference in cystic fibrosis patients
      homozygous for the F508del mutation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Miglustat is an inhibitor of α-glucosidases and other enzymes. Oral miglustat is currently
      marketed in Europa and US for the treatment of Gaucher type 1 patients for whom enzyme
      replacement treatment is not an option.

      Gastro-intestinal side effects are common with this formulation. This medication has been
      shown to have a beneficial effect both on Cl- an Na+ transports in cystic fibrosis epithelial
      cells. In addition, a single airway delivery of low-dose Miglustat normalizes nasal potential
      difference (NPD) in F508del cystic fibrosis mice. NPD abnormalities specific of CF patients
      are considered to reflect the primary defect of CFTR protein so that any curative treatment
      is expected to correct them at least partially.

      In the field of respiratory pharmacology, it is a general rule that the inhaled route is to
      be favoured whenever possible : it is usually more effective despite much lower doses and
      systemic absorption (which also implies lower costs and improved tolerance).

      The aim of this study is to investigate the effect of a single local administration of
      Miglustat on NPD measurements in CF patients homozygous for the F508del mutation.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change in response to Chloride-free solution and isoproterenol ( reflecting chloride transport)</measure>
    <time_frame>change from baseline ( visit 1) and placebo to miglustat instillation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>change in basal voltage value and in amiloride response ( reflecting sodium transport)</measure>
    <time_frame>change from baseline (visit1) and placebo to miglustat instillation</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>Baseline</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Visit 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Miglustat</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Nasal instillation of Miglustat (visit 2 or 3)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Nasal instillation of placebo (visit 3 or 2)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Miglustat</intervention_name>
    <description>Nasal instillation of miglustat</description>
    <arm_group_label>Miglustat</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Nasal instillation of placebo matching in appearance with the Miglustat instillation</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Cystic fibrosis patients homozygous for the F508del mutation as confirmed by genetic
             test

          -  Aged 14 years and older

          -  Male or female (non-pregnant women who are to remain non-pregnant for 3 months after
             the end of the study)

          -  FEV1 &gt; 50% of predicted normal

        Exclusion Criteria:

          -  Acute respiratory tract infection or pulmonary exacerbation requiring antibiotic
             intervention within 2 weeks of visit 1

          -  Any condition prohibiting the correct measurement of the NPD such as respiratory tract
             infection

          -  Active or passive smoking

          -  Allergic chronic rhinitis

          -  History of significant lactose intolerance

          -  History of neuropathy

          -  History of cataracts or known increased risk of cataract formation

          -  Hypersensitivity to miglustat or any excipients

          -  Planned treatment or treatment with another investigational drug or therapy within 1
             month prior to randomisation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrick LEBECQUE, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cliniques Universitaires St Luc (Université Catholique de Louvain )</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Teresinha LEAL, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cliniques Universitaires St. Luc ( Université Catholique de Louvain)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cliniques Universitaires St Luc (Université Catholique de Louvain) 10 avenue Hippocrate</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <reference>
    <citation>Lubamba B, Lebacq J, Lebecque P, Vanbever R, Leonard A, Wallemacq P, Leal T. Airway delivery of low-dose miglustat normalizes nasal potential difference in F508del cystic fibrosis mice. Am J Respir Crit Care Med. 2009 Jun 1;179(11):1022-8. doi: 10.1164/rccm.200901-0049OC. Epub 2009 Mar 19.</citation>
    <PMID>19299496</PMID>
  </reference>
  <reference>
    <citation>Norez C, Noel S, Wilke M, Bijvelds M, Jorna H, Melin P, DeJonge H, Becq F. Rescue of functional delF508-CFTR channels in cystic fibrosis epithelial cells by the alpha-glucosidase inhibitor miglustat. FEBS Lett. 2006 Apr 3;580(8):2081-6. Epub 2006 Mar 10.</citation>
    <PMID>16546175</PMID>
  </reference>
  <reference>
    <citation>Noël S, Wilke M, Bot AG, De Jonge HR, Becq F. Parallel improvement of sodium and chloride transport defects by miglustat (n-butyldeoxynojyrimicin) in cystic fibrosis epithelial cells. J Pharmacol Exp Ther. 2008 Jun;325(3):1016-23. doi: 10.1124/jpet.107.135582. Epub 2008 Feb 28.</citation>
    <PMID>18309088</PMID>
  </reference>
  <reference>
    <citation>Norez C, Antigny F, Noel S, Vandebrouck C, Becq F. A cystic fibrosis respiratory epithelial cell chronically treated by miglustat acquires a non-cystic fibrosis-like phenotype. Am J Respir Cell Mol Biol. 2009 Aug;41(2):217-25. doi: 10.1165/rcmb.2008-0285OC. Epub 2009 Jan 8.</citation>
    <PMID>19131642</PMID>
  </reference>
  <verification_date>August 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 23, 2009</study_first_submitted>
  <study_first_submitted_qc>July 23, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 24, 2009</study_first_posted>
  <last_update_submitted>August 9, 2011</last_update_submitted>
  <last_update_submitted_qc>August 9, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 10, 2011</last_update_posted>
  <responsible_party>
    <name_title>Patrick Lebecque, MD, PhD</name_title>
    <organization>Cliniques universitaires Saint Luc (Université Catholique de Louvain)</organization>
  </responsible_party>
  <keyword>Cystic fibrosis</keyword>
  <keyword>miglustat</keyword>
  <keyword>nasal instillation</keyword>
  <keyword>nasal potential difference</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Cystic Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Miglustat</mesh_term>
    <mesh_term>1-Deoxynojirimycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

